BPC-157 musculoskeletal research: systematic review

Introduction

BPC-157 gets a lot of attention in online forums, but attention and evidence aren’t the same thing. A systematic review published in 2025 — now indexed on PubMed Central — did something the field has needed for a while: it gathered and critically assessed the peer-reviewed preclinical evidence for BPC-157 in orthopaedics and sports medicine.

This post breaks down what the review found, what it specifically didn’t claim, and what the individual tissue-level data actually looks like.

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a protein found in human gastric juice. Predrag Sikiric and his group at the University of Zagreb first characterised it in the 1990s, and the same group has produced the majority of the published literature since then — over 100 preclinical papers.

Despite three decades of study, BPC-157 has no FDA approval and no approval from any major regulatory body for human therapeutic use. Researchers are interested in its apparent effects on tissue healing, angiogenesis, inflammation modulation, and growth factor receptor expression.

The Systematic Review

Citation: Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Published in a peer-reviewed orthopaedic journal, 2025. PMC-indexed: PMC12313605

The review screened 544 articles from 1993–2024 and included 36 studies: 35 preclinical and 1 clinical. The preclinical work spans four musculoskeletal tissue types: tendon, ligament, muscle, and bone.

Tendon Research

The tendon data is probably the strongest in the BPC-157 literature, and the Achilles tendon model has received the most attention.

Staresinic et al. (2003) published the foundational study in the Journal of Orthopaedic Research, showing that BPC-157 accelerated healing of transected rat Achilles tendons. Treated animals showed improved biomechanical outcomes: higher load to failure, higher load to failure per area, and increased Young’s modulus of elasticity. Histologically, BPC-157-treated tendons had more organised collagen deposition, better fibroblast proliferation, and less inflammatory infiltrate than controls.

Chang et al. (2011) followed up in the Journal of Applied Physiology, demonstrating that BPC-157 promoted tendon healing through three specific mechanisms: enhanced tendon outgrowth from explants, improved cell survival under stress conditions, and increased migration of tendon fibroblasts. They identified the FAK-paxillin signalling pathway as the likely mediator of the migration effect.

A 2018 study in Molecules (Chang et al.) added another layer: BPC-157 upregulated growth hormone receptor (GHR) expression in tendon fibroblasts, suggesting a mechanism by which the peptide could amplify local repair signals at injury sites.

Ligament Research

Cerovecki et al. (2010) published in the Journal of Orthopaedic Research, testing BPC-157 in a rat medial collateral ligament (MCL) transection model. BPC-157-treated animals showed consistent improvements across functional, biomechanical, macroscopic, and histological measures compared to controls.

Functionally, the treated rats bore weight earlier and moved more normally. Biomechanically, their ligaments had greater tensile strength. Histologically, the healing tissue showed better collagen organisation and more mature fibroblast populations. The effect wasn’t subtle — the authors described it as “consistent functional, biomechanical, macroscopic and histological healing improvements.”

What’s notable here is that the ligament findings parallel the tendon results. Same peptide, different tissue type, similar pattern of improvement across the same categories of outcome measure.

Muscle Research

Muscle injury models are less extensively published than tendon work, but the available data follows a consistent pattern. Novinscak et al. demonstrated that BPC-157 improved recovery in a rat muscle crush injury model, with treated animals showing faster functional recovery and better histological healing than controls.

The systematic review noted that across muscle injury studies, BPC-157 was associated with improved weight-bearing, better movement quality, and faster return to normal task performance in animal models. The proposed mechanism involves both direct effects on muscle cell proliferation and indirect effects through enhanced angiogenesis — new blood vessel formation that delivers repair factors to the injury site.

The muscle data is thinner than the tendon data, and the models used are more varied, making direct comparison across studies harder. This is an area that needs more standardised investigation.

Bone Research

The bone healing literature is the most recent addition to the BPC-157 musculoskeletal story. Preclinical studies have tested the peptide in fracture models, segmental bone defect models, and conditions mimicking compromised healing such as avascular osteonecrosis.

In rabbit segmental bone defect models, BPC-157 treatment produced callus formation roughly twice the size of controls after two weeks. The effect was comparable to traditional bone marrow grafts — which is a striking result for a 15-amino acid peptide. The proposed mechanism centres on the VEGFR2-NO signalling pathway: BPC-157 appears to stimulate angiogenesis within bone tissue and enhance osteoblast activity, improving bone matrix deposition and fracture consolidation.

These are encouraging findings, but they come from a small number of studies and the long-term biomechanical outcomes of BPC-157-treated bone haven’t been thoroughly characterised.

Summary of Key Preclinical Studies

Proposed Mechanisms

The systematic review identified three main mechanistic threads running through the BPC-157 literature:

1. Growth hormone receptor upregulation — BPC-157 appears to increase GHR expression at injury sites, amplifying local repair signals. This may explain why the effects are most pronounced in tissues with active injury rather than in healthy tissue.
2. Angiogenesis — Multiple studies show BPC-157 promotes new blood vessel formation, likely through VEGF and NO-mediated pathways. Blood supply is the rate-limiting factor in most tissue repair, so this could be the most functionally important mechanism.
3. Anti-inflammatory effects — Reduced levels of pro-inflammatory cytokines (TNF-alpha, IL-6) have been observed in treated tissues. Less inflammation at the injury site may allow repair processes to proceed more efficiently.

The Human Data Problem

Here’s where honesty matters. The review found exactly one human study: a small retrospective analysis of 12 patients with chronic knee pain who received intraarticular BPC-157 injections. Seven of the twelve reported pain and function improvement lasting over six months.

This is not a clinical trial. There was no control group, no blinding, and a sample size of 12. It shouldn’t be cited as evidence of efficacy in humans — the reviewers themselves treat it as preliminary at best.

The preclinical evidence is consistent, mechanistically plausible, and spans multiple tissue types. But the leap from “works in rats” to “works safely in humans” is enormous. Many promising preclinical compounds fail in human trials. The field needs proper Phase I/II/III trials, and that’s exactly what the review authors call for.

What the Review Doesn’t Claim

Because online discussions tend to run ahead of the evidence:

• The review does not conclude that BPC-157 is safe or effective in humans
• The review does not recommend clinical use
• The authors describe the evidence as “mainly preclinical” and explicitly call for human trials
• STAT News quoted the lead author saying BPC-157 “should not be used by humans” outside of clinical trials

Regulatory Context

As of March 2026, BPC-157 remains a research-only compound. The FDA placed it on Category 2 in 2023, restricting compounding pharmacy access. HHS Secretary RFK Jr. has announced intent to review this status, but no formal regulatory changes have been published.

Regardless of compounding status, BPC-157 is not approved for human therapeutic use. This site’s content pertains solely to laboratory and research applications.

Conclusion

The Vasireddi et al. systematic review is the most thorough assessment of BPC-157’s musculoskeletal evidence to date. The preclinical results are consistent across tendon, ligament, muscle, and bone models, and the proposed mechanisms — GHR upregulation, angiogenesis, anti-inflammatory effects — are plausible and supported by multiple independent observations.

But the human data barely exists. Until well-designed clinical trials are conducted, BPC-157 remains a compound of genuine research interest sitting on top of a large evidence gap. The preclinical foundation is there. The clinical work hasn’t been done yet.

Related articles on Amino Research

• RFK Jr., the FDA, and 14 Peptides: What the Regulatory Shift Means for Research
• The Peptide Boom: Why the Market Is Doubling by 2033
• CJC-1295: A Complete Research Guide
• Epithalon: The Telomere Peptide with 40 Years of Research